COVID19 🦠 Newsbites
Trump adviser Peter Navarro pressured officials to reward untested companies connected to the White House with lucrative COVID-19 contracts, House inquiry says
  • Peter Navarro, Trump's former trade adviser, is accused of rewarding companies with White House links.
  • Trump officials steered contracts to companies without "adequate diligence," a House inquiry says.
  • On one occasion, Navarro pushed for a brand-new start-up to secure a $354 million contract.
A senior adviser to former President Donald Trump pushed agency officials to secure huge COVID-19 contracts for politically connected and untested firms, according to documents from an inquiry by the Select Subcommittee on the Coronavirus Crisis.

Peter Navarro, who served as a trade adviser to Trump, is one of the officials accused of pursuing a "haphazard and ineffective approach to procurement" and steering contracts "to particular companies without adequate diligence or competitions."

There are numerous examples outlined in the inquiry of how the Trump aide played a significant role in rewarding multimillion-dollar deals to companies with connections to the White House,
ProPublica reported.

On one occasion, Navarro awarded a $96 million deal for respirators to a company with links to the administration — Airboss Defense Group (ADG).

Retired Army general Jack Keane, a Trump ally and paid consultant for ADG, sent a catalog of the company's items to Navarro on March 22, 2020. Keane had just been awarded the Presidential Medal of Freedom by Trump days earlier.

Navarro and members of the White House Coronavirus Task Force had a phone call with representatives from ADG later that day, according to the House inquiry.

Then, a day after the call, ADG submitted a $96.4 million proposal to Navarro's team. He responded by telling the firm in an email that they could "consider it done," the documents show.

Federal Emergency Management Agency officials were quickly sent an invoice and pressured into signing the contract, ProPublica said.

On another occasion, the Trump aide pushed for an untested pharmaceutical company to sign a major deal to produce pharmaceutical ingredients and generic drugs.

The $354 million contract went to a newly-formed start-up, Phlow. "It was the largest contract ever awarded by BARDA (Biomedical Advanced Research and Development Authority), even though Phlow was a first-time government contractor that had incorporated just months earlier in January 2020," documents from the Select Subcommittee show.

Navarro had been introduced to Phlow's chief executive months earlier, the documents say. He had also developed a friendship with a Phlow board member over their shared China skepticism, Insider's Tom Porter reported.

The Trump aide also put pressure on agency officials to get the deal done quickly, the inquiry finds. "My head is going to explode if this contract does not get immediately approved," Navarro wrote to BARDA officials.

The former trade adviser is accused of coordinating with executives at the Eastman Kodak Company. The photography business has a "complete lack of experience in the field," the subcommittee's letter says. Nevertheless, the firm entered into a letter of intent in June 2020 to manufacture pharmaceutical agents.
Read the full article:

Pope Francis Advocates Universal Vaccine Access in Easter Message

Francis on Sunday called on world leaders to ensure access to coronavirus vaccines for all. The remarks, part of his annual Easter message, were delivered in front of a small group of worshipers inside St. Peter’s Basilica.
Read the full article:

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in Wuhan, China, in December 2019. It has since spread worldwide, leading to an ongoing pandemic.

Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Most people (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) and 5% of patients suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). At least a third of the people who are infected with the virus remain asymptomatic and do not develop noticeable symptoms at any point in time, but can spread the disease. Some patients continue to experience a range of effects—known as long COVID—for months after recovery and damage to organs has been observed. Multi-year studies are underway to further investigate the long term effects of the disease.

Source: Coronavirus disease 2019 - Wikipedia